Table 5:
Postoperative changes in median work productivity impairment (%) among currently employed study participants with CRS (n=106) across independent characteristics
| Preoperative characteristics / comorbidity: | N | Preoperative Median [IQR] | Postoperative Median [IQR] | Absolute Δ Median [IQR] | p-value |
|---|---|---|---|---|---|
| Age: 18–40 | 38 | 40.8% [45.0%] | 9.4% [23.0%] | 15.7% [43.0%] | <0.001 |
| Age: 41–65 | 60 | 26.2% [54.0%] | 0.0% [19.0%] | 10.0% [30.0%] | <0.001 |
| Age: ≥65 | 8 | 10.0% [29.0%] | 0.0% [8.0%] | 10.0% [37.0%] | 0.395 |
| Males | 54 | 14.8% [37.0%] | 0.0% [10.0%] | 10.0% [30.0%] | <0.001 |
| Females | 52 | 40.8% [52.0%] | 10.0% [30.0%] | 19.6% [42.0%] | <0.001 |
| White/Caucasian | 94 | 29.4% [52.0%] | 0.0% [20.0%] | 10.0% [30.0%] | <0.001 |
| African American | 9 | 48.0% [72.0%] | 0.0% [23.0%] | 25.7% [49.0%] | 0.028 |
| Asian | 1 | 33.5% [0.0%] | 15.5% [0.0%] | 18.0% [0.0%] | 0.317 |
| American Indian/Alaska native | 2 | 35.2% [----] | 9.4% [----] | 25.8% [----] | 0.180 |
| Hispanic/Latino ethnicity | 4 | 33.3% [83.0%] | 0.0% [15.0%] | 33.3% [68.0%] | 0.180 |
| Education level completed: | |||||
| High school | 23 | 27.4% [63.0%] | 11.1% [30.0%] | 0.0% [26.0%] | 0.112 |
| Post-secondary | 53 | 37.4% [52.0%] | 0.0% [20.0%] | 18.0% [43.0%] | <0.001 |
| Graduate school | 30 | 19.8% [38.0%] | 0.0% [10.0%] | 10.0% [30.0%] | <0.001 |
| Household income category: | |||||
| $0-$25,000 | 12 | 57.4% [57.0%] | 22.5% [64.0%] | 21.1% [51.0%] | 0.074 |
| $26,000 - $50,000 | 20 | 38.7% [56.0%] | 4.5% [28.0%] | 14.5% [32.0%] | 0.003 |
| $51,000 - $75,000 | 15 | 39.0% [31.0%] | 15.5% [49.0%] | 20.0% [30.0%] | 0.016 |
| $76,000 - $100,000 | 17 | 10.0% [56.0%] | 0.0% [0.0%] | 10.0% [53.0%] | 0.008 |
| $100,000+ | 34 | 15.0% [38.0%] | 0.0% [20.0%] | 9.4% [30.0%] | 0.009 |
| Unknown / unwilling to provide | 8 | 30.8% [55.0%] | 0.0% [8.0%] | 30.8% [53.0%] | 0.018 |
| CRSsNP | 40 | 39.5% [52.0%] | 4.9% [20.0%] | 18.5% [44.0%] | <0.001 |
| CRSwNP | 66 | 25.4% [43.0%] | 0.0% [18.0%] | 10.0% [28.0%] | <0.001 |
| Previous sinus surgery: None | 50 | 28.1% [37.0%] | 0.0% [18.0%] | 10.0% [43.0%] | <0.001 |
| Previous sinus surgery: ≥1 | 56 | 30.0% [54.0%] | 1.7% [29.0%] | 12.9% [30.0%] | <0.001 |
| Fungal ball | 1 | 0.0% [0.0%] | 0.0% [0.0%] | 0.0% [0.0%] | >0.999 |
| Odontogenic sinusitis | 1 | 20.0% [0.0%] | 0.0% [0.0%] | 20.0% [20.0%] | 0.317 |
| Asthma | 55 | 30.0% [57.0%] | 0.0% [20.0%] | 10.0% [30.0%] | <0.001 |
| Migraine | 21 | 44.0% [58.0%] | 10.0% [53.0%] | 23.3% [51.0%] | 0.007 |
| Diabetes mellitus | 7 | 10.0% [72.0%] | 0.0% [15.0%] | 10.0% [56.0%] | 0.068 |
| Depression | 36 | 39.5% [48.0%] | 8.5% [28.0%] | 19.1% [44.0%] | <0.001 |
| Anxiety | 30 | 30.0% [59.0%] | 5.7% [20.0%] | 18.5% [50.0%] | 0.002 |
| Obstructive sleep apnea | 13 | 33.5% [68.0%] | 0.0% [28.0%] | 18.0% [43.0%] | 0.018 |
| Tobacco use (current) | 3 | 0.0% [----] | 0.0% [0.0%] | 0.0% [----] | 0.317 |
| Tobacco use (former) | 18 | 26.2% [73.0%] | 5.0% [53.0%] | 9.4% [26.0%] | 0.118 |
| Tobacco use (none) | 85 | 30.0% [50.0%] | 0.0% [19.0%] | 16.5% [42.0%] | <0.001 |
| Alcohol use (current) | 55 | 26.2% [34.0%] | 0.0% [20.0%] | 15.0% [30.0%] | <0.001 |
| AERD | 21 | 20.0% [52.0%] | 0.0% [10.0%] | 8.9% [50.0%] | 0.003 |
| Allergic rhinitis | 56 | 30.0% [53.0%] | 0.0% [20.0%] | 13.6% [36.0%] | <0.001 |
| Allergy | 63 | 30.0% [52.0%] | 8.0% [26.0%] | 10.0% [30.0%] | <0.001 |
| Primary ciliary dyskinesia / CF | 1 | 62.5% [0.0%] | 20.0% [0.0%] | 42.5% [0.0%] | 0.317 |
| Autoimmune disease | 12 | 42.4% [68.0%] | 15.0% [57.0%] | 5.0% [58.0%] | 0.093 |
| Oral corticosteroid dependency | 11 | 44.8% [54.0%] | 8.0% [30.0%] | 26.2% [79.0%] | 0.011 |
| Lund-Kennedy endoscopy score: ≥ 7* | 56 | 30.0% [53.0%] | 0.0% [20.0%] | 13.6% [30.0%] | <0.001 |
| Lund-Kennedy endoscopy score: < 7 | 48 | 28.7% [60.0%] | 0.0% [20.0%] | 10.0% [43.0%] | <0.001 |
| Lund-Mackay CT score: ≥ 14* | 66 | 23.7% [52.0%] | 0.0% [20.0%] | 10.0% [30.0%] | <0.001 |
| Lund-Mackay CT score: < 14 | 40 | 38.7% [48.0%] | 0.0% [20.0%] | 20.2% [43.0%] | <0.001 |
| SNOT-22 total score: ≥48* | 54 | 47.0% [51.0%] | 10.0% [33.0%] | 19.1% [51.0%] | <0.001 |
| SNOT-22 total score: <48 | 52 | 10.0% [29.0%] | 0.0% [10.0%] | 10.0% [26.0%] | <0.001 |
P-values associated with Wilcoxon signed-rank testing. IQR, interquartile range as a difference between the first quartile (Q1) and third quartile (Q3); CRS, chronic rhinosinusitis; CRSsNP, CRS without nasal polyposis; CRSwNP, CRS with nasal polyposis; ASA, acetylsalicylic acid; AERD, aspirin exacerbated respiratory disease; CF, cystic fibrosis; CT, computed tomography.
*
median score threshold values.